93 5721 (Buprenorphine hydrochloride and naloxone hydrochloride (sublingual) 8 mg (base) / 2 mg (base))
Pill imprint 93 5721 has been identified as Buprenorphine hydrochloride and naloxone hydrochloride (sublingual) 8 mg (base) / 2 mg (base).
Buprenorphine/naloxone is used in the treatment of opiate dependence and belongs to the drug class narcotic analgesic combinations. Risk cannot be ruled out during pregnancy. Buprenorphine/naloxone 8 mg (base) / 2 mg (base) is classified as a Schedule 3 controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- 93 5721
- Strength:
- 8 mg (base) / 2 mg (base)
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Narcotic analgesic combinations
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- 3 - Moderate abuse potential
- Manufacturer:
- Teva Pharmaceuticals USA Inc.
More about buprenorphine/naloxone
Consumer resources
- Buprenorphine and naloxone
- Buprenorphine and naloxone film
- Buprenorphine/naloxone
- Buprenorphine/naloxone film
- Buprenorphine and naloxone oral/sublingual
- Buprenorphine/naloxone Oromucosal, Sublingual (Advanced Reading)
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
